Novel Biomarkers of Gastrointestinal Cancer
Gastrointestinal (GI) cancer is a major cause of morbidity and mortality in the world. Since early diagnosis and optimal treatment selection are crucial to improving the prognosis of these diseases, the discovery of useful biomarkers has the potential to greatly reduce their burden. Recent technical...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_97442 | ||
| 005 | 20230220 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230220s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-4932-3 | ||
| 020 | |a 9783036549316 | ||
| 020 | |a 9783036549323 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-4932-3 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MJCL |2 bicssc | |
| 100 | 1 | |a Shimura, Takaya |4 edt | |
| 700 | 1 | |a Shimura, Takaya |4 oth | |
| 245 | 1 | 0 | |a Novel Biomarkers of Gastrointestinal Cancer |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (248 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Gastrointestinal (GI) cancer is a major cause of morbidity and mortality in the world. Since early diagnosis and optimal treatment selection are crucial to improving the prognosis of these diseases, the discovery of useful biomarkers has the potential to greatly reduce their burden. Recent technical and mechanical developments have allowed for the detection of tiny differences in various factors modified in physical conditions, which could contribute to the discovery of novel biomarkers for some diseases.In this Special Issue, we aim to focus on novel biomarkers for GI cancers, including esophageal cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer and biliary cancer. In addition, any samples (tissue, blood, urine and feces) are useful as biomarker sources, although body-fluid-based biomarkers are promising as diagnostic biomarkers due to their noninvasiveness. This Special Issue aims to collect novel insights clarifying the current situation and future perspective in this field. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Oncology |2 bicssc | |
| 653 | |a colorectal cancer | ||
| 653 | |a advanced adenoma | ||
| 653 | |a screening | ||
| 653 | |a stool | ||
| 653 | |a mRNA | ||
| 653 | |a n/a | ||
| 653 | |a cancer screening | ||
| 653 | |a cirrhosis | ||
| 653 | |a AFP | ||
| 653 | |a machine learning | ||
| 653 | |a MALDI-TOF | ||
| 653 | |a proteomics | ||
| 653 | |a CXCR4 | ||
| 653 | |a prognosis | ||
| 653 | |a overall survival | ||
| 653 | |a rectal cancer | ||
| 653 | |a neoadjuvant chemoradiation | ||
| 653 | |a mouse model | ||
| 653 | |a biomarkers | ||
| 653 | |a urokinase plasminogen activator (uPA) | ||
| 653 | |a urokinase plasminogen activator receptor (uPAR) | ||
| 653 | |a plasminogen activator inhibitor type 1 (PAI-1) | ||
| 653 | |a circulating tumour cell (CTC) | ||
| 653 | |a gastric cancer | ||
| 653 | |a oesophageal cancer | ||
| 653 | |a serine proteases | ||
| 653 | |a tumour microenvironment | ||
| 653 | |a serpins | ||
| 653 | |a biomarker | ||
| 653 | |a chemoresistance | ||
| 653 | |a liquid biopsy | ||
| 653 | |a microRNA | ||
| 653 | |a long non-coding RNA | ||
| 653 | |a colorectal neoplasms | ||
| 653 | |a cancer screening tests | ||
| 653 | |a early detection of cancer | ||
| 653 | |a precision medicine | ||
| 653 | |a unfolded protein | ||
| 653 | |a hepatocellular cancer | ||
| 653 | |a GSVA | ||
| 653 | |a unfolded protein score | ||
| 653 | |a epigenetic regulation genes | ||
| 653 | |a somatic mutations | ||
| 653 | |a molecular genetic markers | ||
| 653 | |a extracellular vesicles | ||
| 653 | |a microbiome | ||
| 653 | |a 16S rRNA amplicon | ||
| 653 | |a metagenomics | ||
| 653 | |a liver fibrosis | ||
| 653 | |a hepatocellular carcinoma | ||
| 653 | |a recurrence | ||
| 653 | |a SHG/TPEF microscopy | ||
| 653 | |a artificial intelligence | ||
| 653 | |a advanced gastric cancer | ||
| 653 | |a targeted therapy | ||
| 653 | |a urinary miRNA | ||
| 653 | |a miR-129-1-3p | ||
| 653 | |a miR-566 | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5937 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/97442 |7 0 |z DOAB: description of the publication |